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INTRODUCTION 
                      "GOD'S FIRST CANCER MAN'S FIRST CURE" 
What remained as a therapeutic trap & an enigmatic disease until 1956 
emerged as a fascinating curable malignancy with the advent of methotrexate. Serum 
assays to accurately measure human chorionic gonadotropin (hCG) & diagnostic 
sonological imaging is definitely a landmark in the history of gestational trophoblastic 
diseases. 
Gestational Trophoblastic disease is an umbrella term used to describe the 
heterogeneous group of interrelated lesions that arise from abnormal proliferation of 
placental trophoblast. Gestational Trophoblastic diseases are histopathologically 
different and can be Benign and malignant. All forms of Gestational Trophoblastic 
disease produce β Human chorionic gonadotrophin. Hence it is an excellent tool for 
screening, arriving at diagnosis, for monitoring therapeutic response and for follow up 
of the disease. 
Since prenatal care is sought much earlier now a days and sonography is 
virtually universal, molar pregnancies are detected much earlier and before 
complications ensue with an average gestational age of diagnosis being 10 weeks. But 
post molar pregnancy surveillance requires a longer period of follow up with β-hCG 
with which our Indian women may not be compliant. This study conducted in 
Government rajaji hospital, Madurai from august 2015 to august 2016 is a 
longitudinal prospective cohort study with its aim to prove that uterine artery Doppler 
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changes can predict resolution or persistence of the disease much earlier when 
compared with serial β-hCG follow up, so that uterine artery Doppler monitoring can 
be an equivalent or a better alternative for β-hCG in predicting the course of the 
disease well ahead. 
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AIM OF THE STUDY 
 
Our aim of the study is to evaluate the role of uterine artery Doppler in earlier 
prediction of resolution in post molar pregnancy surveillance compared to serial β-
hCG follow up. 
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HYDATIDIFORM MOLE 
DEFINITION: 
In Latin the word "hydatid" means "drop of water” and the word "mole" 
means "spot”. 
Pathologically, Hydatidiform moles are nothing but placentas with abnormally 
developed chorionic villi with varying amount of proliferative trophoblast with an 
enlarged, edematous and vesicular appearance. 
Trophoblast is comprised of 
• Cytotrophoblast – have an increased mitotic index and do not produce any 
hormone. 
• Syncytiotrophoblast- shows decreased mitotic index, produces beta-human 
chorionic gonadotrophin (--hCG) and constitutes the chorionic villi. 
• Intermediate trophoblast- marker of endometrial implantation and invasion.  
Varying amount of proliferation of each kind of trophoblast constitutes the 
spectrum of gestational trophoblastic diseases. 
WHO Classification3 
Premalignant Diseases 
• Complete Hydatidiform Mole  ( CM ) 
• Partial  Hydatidiform Mole  ( PM )  
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Malignant Diseases (Gestational Trophoblastic Neoplasia)  
• Nonmetastatic  
1. Invasive Mole 
2. Placental site trophoblastic tumor ( PSTT ) 
• Metastatic 
1. Gestational Choriocarcinoma 
EPIDEMIOLOGY1 
 Gestational trophoblastic diseases are common in oriental countries- 
Philippines, China, Indonesia, Japan, India, Central and Latin America and 
Africa.  
 India- 1 in 400 pregnancies 
 Calculated Incidence of complete mole- 1 in 1945 pregnancies partial mole- 1 
in 695 pregnancies 
 Age –Complete moles are most common at the extremes of reproductive age 
groups. 
 The incidence of complete mole rises from 1: 1000 to 1:76; 1:6.5 in subsequent 
pregnancies. 
PATHOPHYSIOLOGY: 
• Molar pregnancy arises due to aberrant fertilization process. 
• Complete mole is androgenetic with a diploid karyotype. 
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Abnormal genetic event in complete mole 
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Abnormal genetic event in partial mole 
 
 
 
 
 
 
•  
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• The abnormal genetic event: Single haploid sperm (23X) and a chromosomally 
empty ovum undergo fertilization followed by duplication of chromosomes and 
zygote formation.  
• There is no maternal contribution-DIANDRIC DIPLOIDY (46 XX). 
• Occasionally two different sperms may fertilize an empty ovum- DIANDRIC 
DISPERMY (46XX, 46XY). 
• Partial moles are usually triploid, formed when two paternal haploid 
chromosomes fertilize a maternal haploid-DISPERMIC FERTILIZATION or 
when a maternal haploid is fertilized by an unreduced diploid sperm-
DIANDRIC TRIPLOIDY 
• Fetal parts and placenta are seen in partial moles. 
• Complete moles have more tendency of persistence and malignant 
transformation than partial moles. 
GENETICS: 
 P57 cycline dependent kinase inhibitor is paternally imprinted gene which is 
maternally expressed. 
 P57 kip2 immunostaining is negative in complete mole in contrast to Partial 
mole, Hydropic abortions & normal placenta. 
 Abnormal Methylation. 
 In cases of Familial recurrent molar pregnancy; Defective locus at 19q 13.4 at 
single gene NALP7, it is member of CATERPILLAR family involved in 
inflammation & Apoptosis in genetic Complete mole.  
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 Three other genes H19, P57, IGF-2. 
 Chorio CA-specific genes deletion 7p12-q11.2; Amplification of 7q21-q31 
region; loss of 8p12-p21.  
 HTERT—human telomerase reverse transcriptase expression in uterine 
contents of cases of complete mole is suggested as a marker for persistent 
disease and malignant transformation.  
CLINICAL PICTURE1: 
Conventionally complete mole was diagnosed with the following 
features,  
• Abnormal Bleeding per vaginum-commonest presentation, 
• Hyperemesis (10%), 
• Early onset gestational hypertension (5%,), 
• Anemia, 
• Uterine size large for date (25%), 
• Hyperthyroidism (10%), 
• Pulmonary trophoblostic emboli, 
• Prominent theca lutin cyst. 
Partial mole presented with less severe symptoms more often 
diagnosed as missed abortion or incomplete miscarriage. 
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 But nowadays, since prenatal care is sought much earlier and 
sonography is virtually universal, the clinical presentations have changed remarkably 
with earlier reduction and before complication ensue. The mean of diagnosis is at 
around ten weeks. 
SONOGRAPHY: 
Sonagraphic imaging remains the mainstay of diagnosing gestational 
trophoblastic disease. The accuracy of pre evacuation diagnosis of molar pregnancy 
increases with increasing gestational age. 
Complete Hydatidiform Mole10 
• UTERINE SIGNS 
i) Uterine enlargement-60%, 
ii) Echogenic mass in endometrial cavity, 
iii) Multiple discrete anechoiec cystic areas with heterogeneous echogenicity in 
the centre - SNOW STORM APPEARANCE- seen in <2/3rds of cases, 
less common in first trimester 
• OVARIAN SIGNS: 
i) Enlarged ovaries, 
ii) Theca lutein cyst- due to hyper stimulation from raised circulating hcg 
levels. 
iii) Theca lutein cysts are often bilateral and multiloculated, do resolve with 
treatment, very rarely may present with hemorrhage or rupture. 
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SNOW STORM APPERANCE of the Complete Mole 
 
 
 
 
 
Theca lutein cyst 
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Sonographic appearance of Partial mole 
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Partial Hydatidiform Mole 
• Partial hydatidiform mole is sonographycally seen as cystic spaces in the 
placenta and the gestational sac has transverse to antero-posterior diameter of 
more than 1.5. 
• Fetus may still be viable but with unusual growth restriction or developmental 
abnormalities. 
• ẞ-hCG in women with complete Hydatidiform mole, the total hCG values 
exceed 1 lakh IU/L. But in partial molar pregnancy hcg levels are within wide 
range associated with normal pregnancy. 
Role of Doppler: 
• Uterine artery Doppler study in early trimester of a normal pregnancy shows 
increased resistance with low diastolic waveforms except for the implantation 
site. 
• With increasing gestational age, there is a gradual fall in resistance indices due 
to physiological trophoblastic arterial invasion. 
• But In molar pregnancy, uterine artery Doppler studies show reduced resistance 
indices with high velocity Doppler waveforms, due to much higher degree of 
arterial invasion by abnormally proliferating trophoblastic tissues. 
• Myometrial Invasion is seen as chaotic mass with loss of vascular delineation 
due to arterio venous shunts and neovascularization. 
• High resistance index after evacuation indicates completeness of evacuation. 
• Low resistance index is an adverse prognostic indicator. 
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MANAGEMENT OF GESTATIONAL TROPHOBLASTIC DISEASE 
Preoperative work up 
• Complete blood count, 
•  Platelets, 
• Clotting time , 
• Liver function tests 
• BUN, 
• Serum creatinine  
• Serum electrolytes  
• Thyroid Profile 
• Chest X ray 
• B-hCG 
• Ultrasound with Doppler 
Termination 
• Regardless of uterine size suction evacuation is the management. 
• Medical evacuation of CHM should be avoided due to the risk of 
embolisation. 
• Pre operative cervical dilatation with osmotic agents like laminaria tent.  
• Prostaglandins and oxytocin induction is not recommended due to the 
risk of bleeding and trophoblastic embolisation. 
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• Cervix should be mechanically dilated to allow the insertion of 10-14 mm 
suction cannula. 
• IV oxytocin should be started after dilatation of the cervix at the initiation 
of suctioning and continued postoperatively to reduce the likelihood of 
hemorrhage. 
• Some degree of trophoblastic deportation into the pelvic venous system 
takes place during molar evacuation. 
• With the large mole –the volume of the tumor may be significant, to 
produce respiratory distress /pulmonary edema.  
• Respiratory distress is treated with the assisted ventilation and monitoring is 
required. 
• Because of deportation trophoblast will thrive within lung parenchyma to 
cause persistent disease and even overt malignancy. 
• Re evacuation of retained molar tissues should never be done. 
• Anti D is mandatory if the mother is Rh negative. 
• Histo pathological examination of the products evacuated should be 
routinely done. 
• A check ultrasound with uterine artery resistance index is done at 48 hours 
post evacuation along with B -hCG. 
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High Risk For Developing Post molar tumor 
 hCG Levels > 100,000 mIU/L 
 Uterine Enlargement > 16 weeks 
 Theca leutin cyst of more than 6 cm in size  
Post suction evacuation follow up: 
o ẞ-hcg within 48 hours after evacuation. 
o Once weekly until two normal values. 
o Once in a month after normal level obtained for six months 
 The protocol for follow up is individualised for each patient based on the type 
of Gestational Trophoblastic Disease. 
 Patients are followed up in GTD clinic once pathologist confirmed diagnosis. 
  i. Partial mole: followed up until β-hCG becomes negative 
  ii. Complete mole: Until 6 months after normal values are obtained  
              iii.Vesicular mole with multiple pregnancy: monthly follow up for 12 months  
In this study the patients were followed up with serial β -hCG at 48 hours, 2nd 
,4th,8th week post evacuation, since the average time for normalization of β- hCG post 
evacuation is around 8- 9 weeks. 
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If  no pathology report is available,  then assume as complete mole and follow 
up 6 months after normalisation. During each follow up, thorough gynaecological 
examination and contraception advice given as, 
 Should NOT conceive until follow up is complete. 
 Use Barrier method until hCG becomes normal 
 Use of combined oral contraceptive pill after normalisation of β- hCG. 
 IUCD are contraindicated due to increased tendency of uterine perforation. 
CLINICAL FEATURES OF GESTATIONAL TROPHOBLASTIC 
NEOPLASIA1 
 Invasive Mole: 
 Clinical diagnosis by plateau or rising titers of β-hCG in the weeks after molar 
evacuation & USG. 
 Persistent bleeding p/v  
 Lower abdominal pain due to invasion in myometrium, vulva, vagina or intra 
abdominal metastasis. 
 It may spread to adjacent pelvic structures, bladder and rectum causing 
hematuria, and bleeding per rectum. 
  Pulmonary metastasis. 
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Placental Site Trophoblastic Tumor (PSTT): 
  Rare slow growing tumor, 
 Mainly from intermediate trophoblast, 
 Menstrual irregularities & lower abdominal pain, galactorrhea due to 
hyperprolactinemia increased h PL 
 Little or no h CG is produced ( Free B hCG fragment ) 
 Rarely  presents as nephrotic syndrome, hematuria or DIC 
 Spread is late, local Infiltration & metastasis is through lymphatic channels. 
Choriocarcinoma:  
 Occurs following any form of pregnancy, mainly after complete mole.  
 Clinical features of bleeding p/v, lower abdominal pain, or in 1/3 of cases no 
pelvic symptoms but symptoms of distant metastasis to lungs, brain, liver, skin, 
cauda equina & the heart may present.    
 Highly malignant, appears as soft purple largely hemorrhagic mass. 
 Microscopic:  implanting blastocyst with central cores of mononuclear 
cytotrophoblast surrounded by rim of multinucleated syncytiotrophoblast & 
distinct absence of chorionic villi with extensive areas of necrosis & 
hemorrhage &frequent evidence of tumor in the sinuses. 
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 The hypervascularity & absence of connective tissue support are the reason for 
its highly malignant behavior. 
NON GYNAECOLOGICAL PRESENTATIONS OF GESTATIONAL 
TROPHOBLASTIC NEOPLASIA1: 
Central Nervous System 
• Sudden collapse or loss of consciousness due to intracranial hemorrhage, 
• Epilepsy/visual field defects, 
Cardio Vascular System 
 Acute embolic complication,  
 Pulmonary hypertension, 
 Very rarely intracavitory tumor of left atrium presenting similar to left Atrial 
myxoma. 
Respiratory System 
 Respiratory failure, 
 Intrathoracic hemorrhage. 
Gastro Intestinal System 
 Massive hemoperitonium, 
 GI bleed secondary to esophageal, gastric and small bowel metastasis. 
Genitourinary System 
 Hematuria 
 Oliguria 
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 Abdominal pain 
 Retroperitonal hemorrhage 
INVESTIGATIONS: 
 Quantitative beta hCG  
 X Ray Chest 
 Pelvic Doppler USG 
 Abdominal Doppler USG to rule out liver & renal metastasis 
 CT chest , abdomen 
 MRI brain 
 Beta hCG in cerebrospinal fluid 
 PET  
 Genetic  studies 
FIGO REQUIREMENT FOR MAKING DIAGNOSIS OF GTN 
1. Four values or more of plateau hCG over at least 3 weeks: days 1, 7, 14 and 21. 
2. A rise of hCG of 10% or greater for 3 values or more over at least 2 weeks: 
days 1, 7, and 14. 
3. Histological diagnosis of choriocarcinoma. 
4. Persistence of hCG beyond 6 months after mole evacuation. 
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ANATOMIC FIGO STAGING SYSTEM FOR GTN (2000)1 
Stage  Criteria  
I.  Disease confined to the uterus  
II.  Disease outside of uterus but is limited to the genital structures  
III.  Disease extends to the lungs with or without known genital tract involvement  
IV.  All other metastatic sites  
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LOW RISK GTN: 
• FIGO score 6 or less.  
• Drugs schedules: single agent chemotherapy 
Most commonly used regimen:- 
Methotrexate: 1 mg/kg 1M on days 1, 3, 5, 7 
Folinic acid 0.1 mg/kg 1M on days, 2, 4, 6 and 8. 
Side Effects: Stomatitis, conjunctivitis, abdominal and chest pain. 
Actinomycin- D: (primary therapy in case of abnormal liver function) 
After the first treatment 
 Further chemotherapy is withheld as long as the HCG level is falling 
progressively 
 Additional single agent chemotherapy is not administered at any predetermined 
or fixed interval 
II course of Chemotherapy if: 
 If HCG level plateaus for more than 3 consecutive weeks or begins to rise 
again. 
 If HCG level does not decline by 1 log within 18 days of completion of first 
treatment, 
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 If response to first treatment was inadequate, dose of MTX is increased from 
1mg/kg/day to 1.5 mg/kg/day for each of the 4 treatment days. 
HIGH RISK GTN: 
 Stage I, II, III With FIGO score 7 or greater or Stage IV  
 Treated with primary intensive combination chemotherapy  
 Regimes given are :  
  MAC. 
 Modified Bagshawe (CHAMOCA) 
 EMA-CO 
 EMA-EP. 
MAC III REGIMEN 
Methotrexate 1 mg/kg IM/1V Days 1, 3, 5, 7 
Folinic acid 0.1 mg/kg IM           Days 2, 4, 6, 8 
Actinomycin-D 12 µg/kg IV Days 1-5 
Cyclophosphamide 3 mg/kg IV Days 1-5 
To be repeated every 15 days if no signs of toxicity. 
 EMA CO REGIMEN 
Etoposide, methotrexate, actinomycin D, alternating weekly with 
cyclophosphamide and oncovin. 
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Day 1  
 Actinomycin D 500 micrograms IV push, 
 Etoposide IV 100 mg/m2 over 30-50 min. 
Methotrexate 100 mg/m2 IV infusion over 1 hr and 
Methotrexate 200 mg/m2 IV infusion over 12 hrs   
Day 2  
Actinomycin D 500 micrograms IV push 
Etoposide 100 mg/m2 IV over 30-50 min. 
Folinic acid 15 mg IV push for every 6 hours for 8 doses beginning 24 
hours after methotrexate bolus.  
Day 8 
Vincristine (Oncovin) 1 mg/m2 IV 
Cyclophosphamide 600 mg/m2 IV 
SIDE EFFECT:- Myelosuppresion ,Mucositis , Neuropathy ,Reversible alopecia  
 
EMA-EP REGIMEN 
 In patient resistant to EMA-CO 
On day 8 
 Etoposide- 10 mg/m2 iv. 
 Cisplatin- 80 mg/m2 iv 
  treatment – until 3 consecutive weekly titers normal. 
 2-4 cycles given further after initial normal β -hCG. 
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Management of sites of metastasis 
VAGINAL &PELVIS (30%)-  
 Single agent chemotherapy –for Low risk GTN  
 Combination chemotherapy –for High risk GTN 
 If bleeding occurs-  
• Vaginal packing 
• Wide local excision  
• Arteriographic embolisation of hypogastric arteries. 
PULMONARY(80%): 
 Present as – Chest pain, cough, hemoptysis dyspnoea. 
 X-ray features- Snowstorm 
 Discrete round densities. 
 Pleural effusion 
 Embolic pattern 
Treatment: 
 Single agent chemotherapy-for low risk GTN. 
 Combination –for high risk GTN. 
 Thoracotomy- if pulmonary parenchyma is viable. 
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HEPATIC (10%): 
 Worse prognosis. 
 Usually associated with widespread metastasis Intraperitoneal bleeding may 
occur. 
Treatment: 
 Chemo & concurrent radiation (2000-3000 cGy). 
 Hepatic resection to excise resistant foci. 
CEREBRAL-10% 
 Acute focal neurological deficits. 
 Combination chemo + WBRT (2000-3000). 
 Patients with metastasis on initial evaluation respond better than who develop 
Lesion during therapy. 
 During period of WBRT- Methotrexate in EMA-CO be increased to 1 g/m2 
with Folinic acid rescue.  
For subsequent pregnancy. 
 Ist trimester TVS to confirm normal pregnancy. 
 β-hCG 6 wks after termination of pregnancy . 
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 After effective treatment for non-malignant GTN molar pregnancy occur 
in 2-10% subsequent pregnancies. 
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HUMAN CHORIONIC GONADOTROPIN 
Human chorionic gonadotropin (hCG) is a heterodimeric glycoprotein 
composed of 237 amino acids with a molecular weight of 25.7 kDa, produced by 
human placental syncytiotrophoblast. It has an α (alpha) subunit and β (beta) subunit. 
The α (alpha) subunit is similar to luteinizing hormone, follicle-stimulating hormone, 
and thyroid-stimulating hormone. The β (beta) subunit is unique to hCG. Other forms 
of human chorionic gonadotropin may be present in serum such as nicked hCG, Free β 
subunit, Nicked free β subunit, β subunit without C terminal peptide and β core 
fragment. 
The hormone Human chorionic gonadotropin  promotes and maintains  the 
corpus luteum during early pregnancy by interacting with the luteinizing 
hormone/choriogonadotropin receptor (LHCGR) of the ovary, so that the  corpus 
luteum secretes progesterone during the first trimester. Progesterone inturn enriches 
the uterus with a thick lining of blood vessels and capillaries to sustain the growing 
fetus. 
Being secreted by placental syncytiotrophoblast, the β human chorionic 
gonadotropin hormone is commonly called as “The pregnancy hormone”. Though the 
presence of β-hCG in urine or serum almost always indicates pregnancy, it can be 
produced in the absence of an embryo.  
β human chorionic gonadotropin can be detected in maternal urine and plasma 
as early as 6 to 9 days after ovulation. There is an exponential increase in hCG level 
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with a doubling time of 1.5 days in first 6 weeks, peaks around 1 lakh IU/L at 8 to 10 
weeks, starts decreasing from 12th week and plateaus at approximately 30000 IU/L 
from 20th week until term. In the postpartum period β hCG shows a slower decline 
than intact hCG. All forms of gestational trophoblastic disease produce high levels of 
hCG except for placental site trophoblastic tumor. Hence serial hCG measurement is a 
well known indicator and predictor of the course of the disease, reassuring sustained 
remission, recognizing relapse, and malignant transformation. 
Hyperglycosylated hCG, produced by cytotrophoblast is found in  
• Normal pregnancy 
• Invasive mole 
Elliott et al has proved that four O linked oligosaccharides are the main difference 
between hCG produced by malignancy and normal pregnancy. Lower proportion of 
hyperglycosylated hCG is associated with early pregnancy loss. 
MEASUREMENT OF hCG 
The conventionally used radioimmuno assays based on serum antibodies against intact 
hCG has low specificity due to high cross reactivity with leutinizing hormone, 
following which radioimmuno assays using polyclonal antibodies, specifically against 
β-hCG came into use. Sandwich type assays detect intact hCG only and hence they are 
highly specific. 
False positive hCG suspected if  
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• hCG level plateau at low concentration 
• failure to respond to chemotherapy 
Unnecessary treatment of presumed persistent trophoblastic disease can be avoided by 
urinary hCG measurement as these heterophilic antibodies are not excreted in urine.  
Persistent low elevation of β hCG without clinical evidence of active 
gestational trophoblastic disease is seen in  
• Quiescent gestational trophoblastic neoplasia 
• Pituitary derived hCG 
• Nongestational neoplasia 
• Physiological elevation 
OTHER BIOCHEMICAL PREDICTORS OF PERSISTANT 
TROPHOBLASTIC DISEASE 
Biomarkers like progesterone, inhibin A, Activin A, Human placental lactogen, 
CA 125, Carcinoembryonic antigen, CA 15-3, CA 19-9, Leptin, 17- β estradiol are 
under study as predictors of persistent trophoblastic disease. 
HOOK EFFECT 
• Hook effect first was described by Miles et al in 1976. Very high values can 
lead to erroneous false negative UPT because of oversaturation of the test assay 
by excessive β-hCG hormone—known as hook effect. 
  
• False negative qualitative 
high dose hook effect.
• hCG level in the order of 1×10
occur. 
• High dose hook effect occurs whenever there is a inordinate amount of a 
substance being measured by an immune assay c
antibody complexes to form.
• Below a certain threshold concentration the assay will reflect accurately the 
raising concentration of the substance.
• Past the threshold concentration when incomplete complexes begin to form the 
assay will form falsely 
higher 
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βhCG assay in the above scenario was caused by the 
 
9
 IU/ml is necessary for high dose hook effect to 
ausing incomplete antigen and 
 
 
lower readings as the concentration 
 
rises higher and 
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DURATION OF FOLLOWUP 
The duration of follow up should be dependent on type of GTD. This follow up plan 
can be followed in GTD clinic once pathologist confirmed diagnosis. 
 Partial mole : stop as soon as β-hCG negative 
 Complete mole: 6 months after normalisation  
 Any mole with multiple pregnancy : monthly  for 12 months, 
If no pathology report is available, then assume as complete mole and follow up 6 
months after normalisation. 
 
 
 
 
 
 
 
 
 
 38  
 
THE ULTRASONOGRAM 
 
Over half a century ultrasound has been extensively used to image human 
body.  It was first used as a medical diagnostic tool to image brain by an Austrian 
neurologist, Dr.Karl Theodore Dussik in 1942. Later the practical technology and its 
application have been developed by Prof Ian Donald from Scotland. Now a days 
ultrasound became one of the most extensively used imaging technologies since it is 
portable, free from radiation risk, and inexpensive. Ultrasound images are 
tomographic and can be real time. 
PRINCIPLES 
The working principle of ultrasonogram is based on piezoelectric effect, which 
was discovered by the Curie brothers in 1880 when they subjected quartz to 
mechanical stress generating an electrical charge on the surface. They also discovered 
reverse piezoelectric effect by electrical application produces vibration on quartz. 
Pulse – Echo approach is the working principle in modern medical 
ultrasonogram. The piezo electric crystals in ultrasound transducer are capable of 
producing small ultrasound pulses on electrical stimuli. These pulse waves penetrate 
body tissues of different acoustic impedance. Some waves are reflected back to 
transducer, some penetrates deeper, and some waves are scattered. The returned echo 
signals are combined and processed to produce an image. Hence the ultrasound 
transducer works as both pulse generator and microphone. 
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Parts of ultrasound transducer 
 
 
 
 
 
 
 
 
 
 
 
 
 40  
 
 
 
Curved array transducer 
 
 
Linear array transducer 
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Phased array Transducer 
 
 
 
Transvaginal transducer 
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The frequencies of ultrasound waves are beyond upper limit of audible human 
hearing i.e. more than 20 kHz. Audible human hearing ranges between 20 – 20000Hz. 
The frequency of ultrasound waves used in most medical devices ranges between 1 -
20 MHz. 
MACHINE COMPONENTS 
1. THE TRANSDUCER 
The ultrasound transducer consists of backing material, piezoelectric elements, 
Electrodes and Acoustic lens. 
The transducer converts 
• Electricity--Piezoelectric element oscillation—ultrasonic waves 
• Ultrasonic waves --Piezoelectric element –electricity 
 Types 
• Curved array 
A curvilinear probe uses low frequency ultrasound waves to produce less 
resolution images than linear probe. 
• Linear array 
A linear probe uses high frequency ultrasound to produce high resolution 
images of superficial structures. 
• Phased array 
It gives more depth to allow deep structures through small acoustic window. 
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2. CPU 
3. CONTROL PANEL 
4. MONITOR 
 
DISPLAY MODES 
 B mode – gives two dimensional images 
 M mode – gives two dimensional image and allows motion recording 
 Doppler – measures frequency shift in echo 
 Colour Doppler – colours are used corresponding to frequency shift. 
Red –blood flow toward the probe 
Blue –blood flow away from the probe. 
DOPPLER ULTRASONOGRAM 
Ultrasound Doppler images, whether color Doppler or spectral Doppler, are 
essentially obtained from measurements of movement. From ultrasound transducers, a 
series of pulses is transmitted to detect movement of blood. Echoes from stationary 
tissue are the same from pulse to pulse. But echoes from moving objects exhibit slight 
differences in the time for the signal to be returned to the receiver. These differences 
are measured as the ‘Doppler frequency’ and are processed to produce either a color 
flow display or a Doppler sonogram.  
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Uterine artery Doppler shows normal blood flow 
 
 
Uterine artery Doppler showing high resistance flow and 
low resistance flow respectively 
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UTERINE ARTERY RESISTANCE INDEX  
The Doppler ultrasound is used to evaluate uterine artery by quantifying the 
waveform by measuring the blood flow velocity at peak systole (maximal contraction 
of the heart) and peak diastole (maximal relaxation of the heart). These values are then 
computed to derive a ratio called Uterine Artery Resistance Index (UARI) in which 
the peak of systole is divided by the sum of systole and diastole. 
UARI= peak systole / (peak systole + peak diastole) 
Uterine artery resistance index has been studied extensively in 
• Prediction of development of gestational trophoblastic neoplasia 
• Diagnosis of gestational trophoblastic neoplasia, low uterine artery Doppler 
indices seems to be correlated with invasive disease. 
• Diagnosis of gestational trophoblastic neoplasia associated with methotrexate 
resistance. 
• Detection of high risk pregnancies such as Preeclampsia. 
In our study uterine artery resistance index has been tooled as a marker for earlier 
prediction of resolution in post molar pregnancy surveillance. 
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REVIEW OF LITERATURE 
1. Neda Salih Amin et al 4, 2007 
Neda Salih Amin et al conducted a longitudinal study in Al yarmouk teaching 
hospital from Jan 2006-07. About 25 cases of vesicular mole were assessed by 
measuring the serial β-hCG levels in the pre and post evacuation period and finding its 
relation with changes in the uterine artery blood flow using Doppler indices. 
Out of these 25 cases, 22 patients had steady fall in serum β-hCG level and 
found to be normal at 6th week of post evacuation and also showed a steady rise in the 
Doppler indices from the pre evacuation to 6th week of post evacuation. 2 patients 
showed plateauing of all Doppler indices without any consistent decrease of β-hCG 
and were proved to be persistent gestational trophoblastic disease. 
Neda salih Amin et al, concluded that there was a significant correlation 
between the serial β-hCG serum levels and uterine artery Doppler indices and 
suggested that Doppler indices may be used to predict and define the course of the 
disease.  
2. Qi Zhou et al 5, 2004 
Qi Zhou et al conducted a retrospective analytical study to evaluate the clinical 
utility of sonography with Doppler in the diagnosis and treatment of gestational 
trophoblastic diseases. Doppler examination of about 355 cases of molar pregnancy 
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diagnosed and treated at Xian Jiaotong University in china between 1991 and 2003 
were analyzed in comparison with  patients in normal early pregnancy. 
Out of the 355 patients with gestational trophoblastic disease, 106 patients were 
diagnosed to have complete Hydatidiform mole, 33 patients were diagnosed to have 
partial Hydatidiform mole, 33 patients have choriocarcinoma, and 184 patients have 
invasive Hydatidiform mole. 
Soft tissue invasion and cystic vascular spaces within the myometrium were the 
hallmark of invasive diseases. Complete mole had molar tissue confined to the 
endometrial cavity, while partial mole had thickened hydropic placenta along with the 
fetus. 
In that study the uterine artery Doppler showed resistance indices for 
• Complete Hydatidiform mole – 0.55 ( SD 0.06) 
• Partial Hydatidiform mole – 0.56 (SD 0.04) 
• Invasive Hydatidiform mole – 0.28 ( SD 0.06 ) 
• Choriocarcinoma – 0.25 ( SD 0.05)  
• Normal pregnancy – 0.06 ( SD 0.04) 
With successful chemotherapy the sonographic and Doppler abnormalities of 
invasive disease resolved. 
 48  
 
Qi Zhou et al concluded that the sonography and Doppler imaging are excellent 
tools for the diagnosis of disease, to detect invasion or recurrence and in following the 
effectiveness of chemotherapy. 
3. Diaa Eldeen M Abd El Aal et al 8, 2003 
Diaa Eldeen M Abd El Aal et al conducted a longitudinal study in Assiut 
university hospital to evaluate the correlation between Doppler blood flow and β-hCG 
to predict the course of the disease and follow up after hydatidiform mole evacuation. 
15 cases of molar pregnancy were taken up for the study. Β-hCG and uterine 
artery Doppler indices were studied the day before evacuation of uterus. Those cases 
were followed up every 2 weeks for first two months and every month for six months 
post evacuation. 
Out of 15, twelve patients showed gradual decrease in β-hCG from 1192 ± 697 
to 6 ± 11 IU/ml by the end of second month. The uterine artery resistance index 
increased from 0.55 ± 0.15 to 1.0 ± 0.26 and the pusatality index increased from 1.02 
± 0.47 to 6.12 ± 2.34. 
Two patients showed a slower decrease in β hCG and one showed a fluctuating 
level of β hCG around the same level, while Doppler indices increased in post 
evacuation period for all 15 cases. 
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So the study concluded that Doppler ultrasonography can be used as an 
adjuvant tool in the follow up of hydatidiform mole and can predict the disease 
progression to invasive mole.  
4. Lawrence H. Lin et al 6, 2015 
Lawrence H. Lin et al published a review article on 2015 by reviewing studies 
evaluating the role of Doppler ultrasonography in the diagnosis, disease progression 
and follow up of patients with Gestational Trophoblastic Diseases. 
28 studies conducted until 2014 were included for this review and concluded 
that Doppler ultrasonography findings were used as ancillary tools along with β hCG 
assessment in the diagnosis of gestational trophoblastic neoplasia. The uterine artery 
Doppler velocimetry used in the prediction of trophoblastic neoplasia and 
chemoresistance of trophoblastic neoplasia.   
 5. Flavia Tarabini Castellani Asmer et al 12, 2014 
Flavia Tarabini Castellani Asmer et al, conducted a prospective cohort study at 
three trophoblastic centers in brazil between 2013 -2014, 
• To Compare uterine artery velocimetry before and after complete hydatidiform 
mole evacuation between those women who develop post molar gestational 
trophoblastic neoplasia and those with spontaneous remission. 
• To assess the usefulness of uterine artery Doppler indices as predictor of post 
molar gestational trophoblastic neoplasia. 
 50  
 
246 patients with complete hydatidiform mole were included in the study. 
The pulsatality index (PI), resistive index (RI), and systolic/diastolic ratio (S/D) 
were measured pre evacuation of complete hydatidiform mole and 4 – 6 weeks 
post evacuation of complete hydatidiform mole along with serial β hCG. 
The study results that, those patients who achieved spontaneous remission, 
the uterine artery Doppler indices were increased after evacuation. Those who 
developed post complete hydatidiform molar gestational trophoblastic neoplasia, 
the Doppler indices were decreased significantly.  
Thus the study concluded that pre and post molar evacuation Doppler 
indices can be useful for predicting post molar gestational trophoblastic neoplasia.  
6. Mahrooz malek et al 7, 
Mahrooz malek et al, conducted a prospective study in 19 patients with 
gestational trophoblastic disease. Transvaginal ultrasound and Doppler findings were 
evaluated the day before evacuation and 1st week after evacuation, every 2 weeks for 
next two months and monthly for next 6 months. The study concluded that Doppler 
findings of molar pregnancy have capability to predict the disease progression. 
7. Amit Kyal et al 13, 
Amit Kyal et al conducted a prospective observational study in Kolkata 
medical college from 2011 to 2012 to correlate the uterine artery pulsatality index as a 
predictor for gestational trophoblastic neoplasia response to chemotherapy. 
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22 patients with gestational trophoblastic neoplasia were taken up for the study. 
All the cases were given inj.methotrxate 50mg im on 1,3,5,7 days with inj. folinic acid 
15 mg im on 2,4,6,8 days. Chemotherapy was continued until β hCG becomes 
undetectable and further two more cycles were given. 
Β hCG concentration of these patients at the time of diagnosis ranged from 
1400 – 210000 and Uterine Artery Pulsatality Index ranged from 0.47 – 2.1. The mean 
Uterine Artery Pulsatality Index before chemotherapy was 1.33 and at the end of 16 
weeks was 1.952.  
The study results that fall in β hCG is well correlated with rise in Uterine 
Artery Pulsatality Index. So concluded that Uterine Artery Pulsatality Index as an 
independent predictor for gestational trophoblastic neoplasia response to 
chemotherapy. 
 8. R Agarwal et al 9, 
R Agarwal et al conducted a prospective cohort study to evaluate Uterine 
Artery Pulsatality Index as a predictor of gestational trophoblastic neoplasia resistance 
to methotrexate. The study was conducted from 2008 to 2011 with 206 patients with 
gestational trophoblastic neoplasia. The mean Uterine Artery Pulsatality Index was 
lower in methotrexate resistance group compared to methotrexate response group. 
The study concluded that Uterine Artery Pulsatality Index represents as an 
independent predictor of gestational trophoblastic neoplasia resistant to methotrexate. 
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MATERIALS AND METHODS 
 
This study was conducted at Government Rajaji medical college and Hospital, 
Madurai. 40 patients with clinical & sonographic evidence of hydatidiform mole were 
included in the study after obtaining Ethics committee approval. Informed written 
consent was obtained from the patients who were included in the study. 
STATEMENT: 
To study the role of uterine artery Doppler in predicting the resolution of molar 
pregnancy earlier than serial β-hCG follow up 
AIM OF THE STUDY: 
• To study the changes in uterine artery doppler,before & after the evacuation of 
molar pregnancy along with serial β-hCG follow up  
• To prove that Doppler can predict resolution 8 weeks before the disappearance 
of β-hCG, while persistence was indicated 1-3 weeks before the increase of β-
hCG.  
STUDY DESIGN: 
Longitudinal prospective cohort study 
PERIOD OF STUDY: 
12 months 
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SAMPLE SIZE: 
40 patients of molar pregnancy  
PARTICIPANTS: 
All cases of molar pregnancy recruited from outpatient clinic & hospital 
admissions.  
INCLUSION CRITERIA: 
1. Amenorrheic women  presenting with clinical & sonographic evidence of 
hydatidiform mole, 
2. Patients who have given informed consent to undergo the study, 
EXCLUSION CRITERIA: 
1. Not satisfying inclusion criteria 
2. Lack of written informed consent 
3. Chronic hypertension 
4. Anomalous fetus 
5. Other causes of increased pelvic blood flow like Pelvic inflammatory disease, 
ectopic pregnancy, non trophoblastic pelvic malignancy, uterine arteriovenous 
malformations. 
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METHODOLOGY: 
The patients satisfying inclusion criteria were evaluated the day before 
evacuation of the uterus. This evaluation included:  
1. Clinical assessment involving general, abdominal and bimanual pelvic examination.  
2. Serum level of β-hCG.  
3. Uterine artery Doppler velocimetry – uterine artery resistance index (UARI)  
Then evacuation was done by the means of suction evacuation and specimens 
were sent for histopathology.  
All the cases were given low dose combined oral contraceptive pills after 
evacuation of the molar pregnancy. 
In the follow-up examination post evacuation Uterine artery resistance index 
was recorded 48 hours after evacuation of the uterus and post evacuation serial β-hCG 
levels monitored at 48 hours, 2nd,4th and 8th week respectively. 
Uterine artery examination (both on the right and left sides) was done using 
Transabdomonal probe with pulsed and colour Doppler facilities by our institutional 
radiologist.  
The β-hCG levels were correlated with uterine artery resistance index and 
statistical analysis was done using SPSS version 16 and Microsoft Excel 2007.  
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Groups 
 
Groups Definition Number 
MP Resolution Without Invasive mole progression 36 
MP Progression With Invasive mole progression 4 
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Null Hypothesis 
 
Null Hypothesis : H0  UARI equal to ẞHCG Doppler in predicting the 
resolution of molar pregnancy earlier  
Alternate Hypothesis : 
H1  
UARI better than ẞHCG Doppler in predicting the 
resolution of molar pregnancy earlier  
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Data Analysis 
 Descriptive statistics was done for all data and were reported in terms of mean 
values and percentages. Suitable statistical tests of comparison were done. Continuous 
variables were analyzed with the unpaired t test. Categorical variables were analyzed 
with the Chi-Square Test and Fisher Exact Test. Statistical significance was taken as P 
< 0.05. The data was analyzed using SPSS version 16 and Microsoft Excel 2007. 
  
  
Age  
 
 
 
Age MP Resolution 
MP 
Progression
≤ 20 
years 6 3
21-30 
years 26 0
31-40 
years 4 0
> 40 
years 0 1
Total 36 4
 
 
6
26
4
0
0
5
10
15
20
25
30
MP Resolution
≤ 20 years
58  
 
Combined 
MP 
Resolution 
% 
MP 
Progression 
 9 16.67 75.00
 26 72.22 0.00
 4 11.11 0.00
 1 0.00 25.00
 40 100 100
3
9
0 0 1
MP Progression
Age
21-30 years 31-40 years > 40 years
 
% 
Combined 
% 
 22.50 
 65.00 
 10.00 
 2.50 
 100 
26
4
1
Combined
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Age Distribution MP Resolution MP Progression Combined 
Mean 24.69 26.50 24.875 
SD 4.57 10.88 5.30 
P value  
Unpaired t Test 0.5252 
 
Among the study patients, there was no statistically significant difference in 
relation to age distribution between MP resolution group (mean=24.69, SD=4.57) and 
MP progression group (mean=26.50, SD=5.30) with a p value of >0.05 as per 
unpaired t test. Therefore we fail to reject the null hypothesis that there is no 
difference in age distribution between the study groups. 
 
  
  
Educational Status
 
 
 
Educational 
Status 
MP 
Resolution Progression
Undergraduate 4 
Higher 
Secondary 15 
High School 8 
Middle School 2 
Primary 
School 1 
Illiterate 6 
Total 36 
P value 
Chi Squared Test
 
4
15
8
2
1
6
0
2
4
6
8
10
12
14
16
18
MP Resolution
Undergraduate Higher Secondary
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MP 
 
Combined 
MP 
Resolution 
% 
Progression 
0 4 11.11 
1 16 41.67 
2 10 22.22 
0 2 5.56 
1 2 2.78 
0 6 16.67 
4 40 100 
 
0.2831
0
4
1
16
2
0
1
0
MP Progression Combined
Educational Status
High School Middle School Primary School
 
MP 
% 
Combined 
% 
0.00 10.00 
25.00 40.00 
50.00 25.00 
0.00 5.00 
25.00 5.00 
0.00 15.00 
100 100 
 
10
2 2
6
Illiterate
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Among the study patients, there was no statistically significant difference in 
relation to educational status between MP resolution group (mainly higher secondary-
41.67% followed by illiterate 16.67%) and MP progression group (mainly high school 
– 50.00% followed by higher secondary school – 25%) with a p value of >0.05 as per 
chi squared  test. Therefore we fail to reject the null hypothesis that there is no 
difference in educational status between the study groups. 
 
  
  
Parity 
 
 
 
Parity MP Resolution Progression
Primi 14 
G2A1 1 
G2P1L1 10 
G3P1L0A1 6 
G3P2L1 4 
G5P1L1A3 1 
Total 36 
P value 
Chi Squared Test
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MP Resolution
Primi G2A1
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MP 
 
Combined 
MP 
Resolution 
% 
MP 
Progression 
%
3 17 38.89 75.00
1 2 2.78 25.00
0 10 27.78 0.00
0 6 16.67 0.00
0 4 11.11 0.00
0 1 2.78 0.00
4 40 100 100
 
0.2211
3
17
1
2
0 0 0
1
0
MP Progression
Parity
G2P1L1 G3P1L0A1 G3P2L1 G5P1L1A3
 
 
Combined 
% 
 42.50 
 5.00 
 25.00 
 15.00 
 10.00 
 2.50 
 100 
 
10
6
4
1
Combined
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Among the study patients, there was no statistically significant difference in 
relation to parity status between MP resolution group (mainly primi-38.89% followed 
by G2P1L1 27.78%) and MP progression group (mainly primi – 75.00% followed by 
G2A1 – 25%) with a p value of >0.05 as per chi squared test. Therefore we fail to 
reject the null hypothesis that there is no difference in parity status between the study 
groups. 
 
  
  
Presenting Complaints
 
 
 
Presenting 
Complaints 
MP 
Resolution 
Bleeding PV 28 
Bleeding PV + 
Hyperemesis 1 
Ref as USG shows 
H.mole 6 
?Blighted ovum 1 
Total 36 
P value
Chi Squared Test
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MP Resolution
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MP 
Progression Combined 
MP 
Resolution 
% 
Progression 
3 31 77.78 
1 2 2.78 
0 6 16.67 
0 1 2.78 
4 40 100 
 
 
 
3
31
1 0 0
MP Progression
Presenting Complaints
Ref as USG shows H.mole
 
MP 
% 
Combined 
% 
75.00 77.50 
25.00 5.00 
0.00 15.00 
0.00 2.50 
100 100 
0.2274 
2
6
1
Combined
?Blighted ovum
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Among the study patients, there was no statistically significant difference in 
relation to presenting complaints status between MP resolution group (mainly 
bleeding PV-77.78% followed by USG reference – 16.67%) and MP progression 
group (mainly bleeding PV – 75.00% followed by bleeding PV and hyperemesis – 
25%) with a p value of >0.05 as per chi squared  test. Therefore we fail to reject the 
null hypothesis that there is no difference in presenting complaints status between the 
study groups. 
 
 
  
  
Gestational Age
 
 
Gestational 
Age 
MP 
Resolution Progression
10 weeks 20 
12 weeks 13 
14 weeks 1 
16 weeks 1 
18 weeks 0 
> 18 weeks 1 
Total 36 
 
 
 
 
20
13
1 1 0
0
5
10
15
20
25
MP Resolution
10 weeks 12 weeks
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MP 
 
Combined 
MP 
Resolution 
% 
Progression 
2 22 55.56 50.00
2 15 36.11 50.00
0 1 2.78 0.00
0 1 2.78 0.00
0 0 0.00 0.00
0 1 2.78 0.00
4 40 100 
2
22
2
15
0 0 01 0
MP Progression
Gestational Age
14 weeks 16 weeks 18 weeks
 
MP 
% 
Combined 
% 
 55.00 
 37.50 
 2.50 
 2.50 
 0.00 
 2.50 
100 100 
1 1 0 1
Combined
> 18 weeks
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Gestational Age 
Distribution MP Resolution MP Progression Combined 
Mean 11.19 11.00 11.175 
SD 1.91 1.15 1.84 
P value  
Unpaired t Test 0.8439 
 
Among the study patients, there was no statistically significant difference in 
relation to gestational age distribution between MP resolution group (mean – 11.19, 
Sad – 1.91) and MP progression group (mean – 11.-00, SD – 1.15) with a p value of 
>0.05 as per chi squared test. Therefore we fail to reject the null hypothesis that there 
is no difference in gestational age distribution between the study groups. 
 
  
  
Fundal Height
 
 
Fundal 
Height 
MP 
Resolution 
MP 
Progression
10-12 
weeks 5 
12-14 
weeks 18 
14-16 
weeks 11 
16-18 
weeks 1 
> 18 
weeks 1 
Total 36 
P value 
Chi Squared Test
 
 
5
18
11
1 1
0
5
10
15
20
25
MP Resolution
10-12 weeks
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Combined 
MP 
Resolution 
% 
MP 
Progression 
0 5 13.89 0.00
3 21 50.00 75.00
1 12 30.56 25.00
0 1 2.78 0.00
0 1 2.78 0.00
4 40 100 100
 
0.8712
0
5
3
1
0 0
MP Progression
Fundal Height
12-14 weeks 14-16 weeks 16-18 weeks
 
% 
Combined 
% 
 12.50 
 52.50 
 30.00 
 2.50 
 2.50 
 100 
 
21
12
1 1
Combined
> 18 weeks
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Among the study patients, there was no statistically significant difference in 
relation to fundal height between MP resolution group (mainly 12-14 weeks – 50.00% 
followed by 14-16 weeks – 30.56%) and MP progression group (mainly 12-14 weeks 
– 75.00% followed by 14-16 weeks – 25.00%) with a p value of >0.05 as per chi 
squared  test. Therefore we fail to reject the null hypothesis that there is no difference 
in fundal height status between the study groups. 
 
  
  
  
Hemoglobin 
 
 
 
 
Haemoglobin 
% 
MP 
Resolution Progression
7-10 g/dl 31 
10-11 g/dl 5 
Total 36 
 
 
 
31
5
0
5
10
15
20
25
30
35
40
MP Resolution
70  
MP 
 
Combined 
MP 
Resolution 
% 
MP 
Progression 
3 34 86.11 75.00
1 6 13.89 25.00
4 40 100 100
3
1
MP Progression
Hemoglobin %
7-10 g/dl 10-11 g/dl
 
% 
Combined 
% 
 85.00 
 15.00 
 100 
34
6
Combined
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Haemoglobin 
Distribution MP Resolution MP Progression Combined 
Mean 8.38 8.60 8.405 
SD 1.01 1.24 1.02 
P value  
Unpaired t Test 0.6922 
 
 
Among the study patients, there was no statistically significant difference in 
relation to Hemoglobin distribution between MP resolution group (mean – 8.38, SD – 
1.01) and MP progression group (mean – 8.60, SD – 1.24) with a p value of >0.05 as 
per chi squared  test. Therefore we fail to reject the null hypothesis that there is no 
difference in Hemoglobin distribution between the study groups. 
  
  
USG diagnosis
 
USG 
diagnosis 
MP 
Resolution Progression
Complete 
Mole 33 
Partial 
Mole 3 
Total 36 
P value
Chi Squared Test
 
Among the study patients, there was no statistically significant difference in 
relation to USG diagnosis status between MP resolution group (mainly complete mole 
– 91.47% followed by partial mole 
complete mole – 75.00% followed by partial mole 
as per chi squared  test. Therefore we fail to reject the null hypothesis that there is no 
difference in USG diagnosis status between the study grou
33
3
0
10
20
30
40
MP Resolution
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MP 
 
Combined 
MP 
Resolution 
% 
MP 
Progression 
%
3 36 91.67 75.00
1 4 8.33 25.00
4 40 100 100
 
 
0.2822
– 8.33%) and MP progression group (mainly 
– 25.00%) with a p value of >0.05 
ps. 
3 1
MP Progression
USG diagnosis
Complete Mole Partial Mole
 
 
Combined 
% 
 90.00 
 10.00 
 100 
 
36
4
Combined
  
Corpus Luteal Cyst
 
Corpus 
Luteal 
Cyst 
MP 
Resolution 
MP 
Progression
Present 2 
Absent 34 
Total 36 
P value 
Chi Squared Test
 
Among the study patients, there was no statistically significant difference in 
relation to corpus luteal cyst status between MP resolution group (mainly absent 
94.44% followed by present 
75.00% followed by present 
test. Therefore we fail to reject the null hypothesis that there is no difference in corpus 
luteal cyst status between the study groups.
2
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Combined 
MP 
Resolution 
% 
MP 
Progression 
%
1 3 5.56 25.00
3 37 94.44 75.00
4 40 100 100
 
0.1618
– 5.56%) and MP progression group (mainly absent 
– 25.00%) with a p value of >0.05 as per chi squared  
 
1
3
MP Progression
Corpus Luteal Cyst
Present Absent
 
 
Combined 
% 
 7.50 
 92.50 
 100 
 
– 
– 
3
37
Combined
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Serum ßhCG Level 
 
 
 
 
Serum  ßhCG Level 
(mIU/L) Preevacuation 
Post 
evacuation  
(48 hrs) 
Post 
evacuation  
(2nd wk) 
Post 
evacuation  
(4th wk) 
Post 
evacuation 
(8th wk) 
MP 
Resolution 
Mean 3013.75 493.31 157.17 42.05 0.27 
SD 5972.95 393.98 146.28 28.85 0.33 
MP 
Progression 
Mean 33223.00 4008.75 976.50 1374.95 948.30 
SD 54580.16 5871.20 105.12 1231.10 1366.00 
P value 
Unpaired t Test 0.0012 0.0003 <0.0001 <0.0001 <0.0001 
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Among the study patients, there was a statistically significant difference in 
relation to serum  ßhCG levels distribution between MP resolution group (mean – 
741.31, SD 1272.17) and MP progression group (mean – 8106.30, SD – 11757.16) 
with a p value of <0.05 as per unpaired t test  test. Therefore we reject the null 
hypothesis that there is no difference in serum ßhCG levels distribution between the 
study groups. 
Discussion  
The mean serum ßhCG levels were significantly lesser in MP resolution group 
compared to MP progression group by a mean difference of 7364.99 mIU/L (91% 
lesser). During the preevacuation period there was a 11 times increase in tire of mean 
serum ßhCG levels in MP progression group compared to MP resolution group which 
came down to 8 times increase in 48 hrs post evacuation period, 6 times increase in 
2nd week post evacuation period and started to increase to 33 times more in 4th week 
post evacuation period and finally it was 3838 times increased at 8th week post 
evacuation period.  This difference is significant with a p-value of 0.0003 as per 
unpaired t-test.  
Conclusion  
In this study we can safely conclude that in MP progression group there is 
sustained elevation of serum ßhCG levels compared to MP resolution group in 
patients with molar pregnancy  
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Uterine Artery Resistance Index 
 
 
 
 
Uterine Artery Resistance Index Preevacuation Post evacuation P value  Paired t Test 
MP 
Resolution 
Mean 0.57 0.85 
<0.0001 
SD 0.06 0.07 
MP 
Progression 
Mean 0.65 0.52 
0.0414 
SD 0.06 0.09 
P value  
Unpaired t Test 0.0182 <0.0001  
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Among the study patients, there was a statistically significant difference in 
relation to uterine artery resistance index distribution between MP resolution group 
(mean – 0.71, SD 0.06) and MP progression group (mean – 0.58, SD – 0.07) with a p 
value of <0.05 as per unpaired t test . Therefore we reject the null hypothesis that there 
is no difference in uterine artery resistance index distribution between the study 
groups. 
Discussion  
The mean uterine artery resistance index was significantly higher in MP 
resolution group compared to MP progression group during postevcuation period by a 
mean difference of 0.33 (39% higher). This difference is significant with a p-value of 
<0.0001 as per unpaired t-test.  
The mean uterine artery resistance index was significantly lower in MP 
resolution group during preevacuation compared to post evacuation period by a mean 
difference of 0.28 (33% higher). This difference is significant with a p-value of 
<0.0001 as per paired t-test. 
The mean uterine artery resistance index was significantly higher in MP 
progression group during preevacuation compared to post evacuation period by a 
mean difference of 0.14 (21% higher). This difference is significant with a p-value of 
0.0414 as per paired t-test. 
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Conclusion  
In this study we can safely conclude that uterine artery resistance index has an 
inverse relationship in molar pregnancy pre and post evacuation. In MP progression 
group it significantly decreases in post evacuation period. But in MP resolution group 
it significantly increases in post evacuation period.    
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Time When ẞ
 
 
Time When ẞ 
HCG Reaches 
Normal 
MP 
Resolution Progression
4 weeks 2 
8 Weeks 32 
10 Weeks 1 
12 Weeks 1 
After 
Chemotherapy 0 
Total 36 
P value
Chi Squared Test
 
 
2
32
1 1 0
0
5
10
15
20
25
30
35
MP Resolution
Time When ẞ HCG Reaches Normal
4 weeks 8 Weeks
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 HCG Reaches Normal
MP 
 
Combined 
MP 
Resolution 
% 
Progression 
0 2 5.56 
0 32 88.89 
0 1 2.78 
0 1 2.78 
4 4 0.00 
4 40 100 
 
 
<0.0001
0
2
0
32
0 0
4
MP Progression
10 Weeks 12 Weeks After Chemotherapy
 
 
MP 
% 
Combined 
% 
0.00 5.00 
0.00 80.00 
0.00 2.50 
0.00 2.50 
100.00 10.00 
100 100 
 
1 1
4
Combined
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Among the study patients, there was a statistically significant difference in 
relation to time when ẞ HCG reaches normal between MP resolution group (mainly at 
8 weeks – 88.89%) and MP progression group (mainly after chemotherapy – 100%) 
with a p value of <0.05 as per chi squared test. Therefore we reject the null hypothesis 
that there is no difference in time when ẞ HCG reaches normal status between the 
study groups. 
Discussion  
Majority of the patients in MP resolution group had time when ẞ HCG reaches 
normal between 4- 8 weeks (94.44%). Majority of the patients in MP progression 
group had time when ẞ HCG reaches normal only after chemotherapy (94.44%). The 
incidence of ẞ HCG reaching normal (within 8 weeks) was significantly higher in MP 
resolution group compared to MP progression group a percentage difference of 
88.89% (94% higher). This difference is significant with a p-value of <0.0001 as per 
chi squared-test.  
Conclusion  
In this study we can safely conclude that ẞ HCG returns to normal quicker in 
MP resolution group compared to MP progression group among patients with molar 
pregnancy.  
 
 
  
UARI Vs ẞHCG
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44
MP progression(↓UARI with ↑ or plateau ẞHCG )
UARI Vs ẞHCG 
Yes No
y = 7.07x + 0.7073
R² = 0.668
15000 20000 25000 30000
ẞ HCG
- UARI Correlation
 
 
36
UARI
Linear (UARI)
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UARI Vs ẞHCG 
MP 
Resolution 
(↑UARI with 
↓ẞHCG) 
MP progression(↓UARI 
with ↑ or plateau 
ẞHCG ) 
MP 
Resolution 
(↑UARI with 
↓ẞHCG) % 
MP progression(↓UARI 
with ↑ or plateau 
ẞHCG ) % 
Yes 36 4 90.00 10.00 
No 4 36 10.00 90.00 
Total 40 40 100 100 
P value 
Chi Squared Test <0.0001 
 
 
Pearson’s “r” Correlation -0.709896  
P value 
One way ANOVA Test 
0.0086 
 
 
Among the study patients, there was a statistically significant difference 
between uterine artery resistance index  and ẞ HCG levels in relation MP resolution 
group (↑UARI with ↓ẞHCG – 90.00%) and MP progression group (↓UARI with ↑ or 
plateau ẞHCG – 90.00% )with a p value of <0.05 as per chi squared test. Therefore 
we reject the null hypothesis that there is no difference in UARI Vs ẞHCG status 
between the study groups. 
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Discussion  
The incidence of ↑UARI with ↓ẞHCG was significantly higher in MP 
resolution group compared to MP progression group by a percentage difference of 
80.00% (89% higher). The incidence of (↓UARI with ↑ or plateau ẞHCG was 
significantly higher in MP progression group compared to MP resolution group by a 
percentage difference of 80.00% (89% higher). This difference is significant with a p-
value of <0.0001 as per chi squared-test.  
The increase in levels of UARI correlates negatively and strongly with the 
decrease in ẞHCG levels. This is true 71% of times as per Pearson’s “r” Correlation 
coefficient of -0.709896. For every 0.1 % increase in levels of UARI there is a 
corresponding 7.78 % decrease in ẞHCG level. This is indicated by the linear 
correlation formula y = (7.07x) +0.7073. Since R2is 0.668, “the fitted regression 
equation explains 67% of the variation in Y"(Y= 7.07(ẞHCG level) + 0.7073).  
Thus 1 measurement increase in UARI causes 77.80 mIU/L decrease in ẞHCG 
levels. This variation in UARI measurement in relation to ẞHCG levels correlates 
71% of times and this variation is truly accounted 67% of times.   
Conclusion  
In this study we can safely conclude that variation in UARI measurement in 
relation to ẞHCG levels correlates strongly, inversely and negatively.   
  
Associated Features
 
 
 
Associated 
Features 
MP 
Resolution 
Nil 6 
Anaemia 24 
Hyperemesis 1 
Anaemia + 
Hyperemesis 5 
Pulmonary 
Nodule 0 
Total 36 
P value
Chi Squared Test
 
6
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1
5
0
0
5
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MP 
Progression Combined 
MP 
Resolution 
% 
Progression 
0 6 16.67 
1 25 66.67 
1 2 2.78 
1 6 13.89 
1 1 0.00 
4 40 100 
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2
6
1
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Among the study patients, there was a statistically significant difference in 
relation to occurrence of associated features between MP resolution group and MP 
progression group with a p value of <0.05 as per chi squared test. Therefore we reject 
the null hypothesis that there is no difference in occurrence of associated features 
status between the study groups. 
Discussion  
Majority of the patients in MP resolution group had anemia as the main 
associated feature (66.67%). Majority of the patients in MP progression group had 
anemia, hyperemesis and pulmonary nodule as the main associated features (25.00%).  
The occurrence of associated features was significantly lower in MP resolution group 
compared to MP progression group a percentage difference of 83.33% (80% higher). 
This difference is significant with a p-value of 0.0062 as per chi squared-test.  
Conclusion  
In this study we can safely conclude that in MP progression group occurrence 
of associated features is more common compared to MP resolution group among 
patients with molar pregnancy.  
 
 
 
  
Comparison of Fundal Height and 
Gestational age Vs Type of Mole
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Partial 
Mole 
Combined 
MP 
Resolution 
% 
Progression 
 2 35 91.67 
2 5 8.33 
 4 40 100 
 
 
2
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2
Partial Mole
age Vs Type of Mole
Fundal Height ≤ Gestational Age
 
MP 
% 
Combined 
% 
50.00 87.50 
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100 100 
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5
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           Among the study patients, there was a statistically significant difference 
in comparison of fundal height and gestational age vs. type of mole with a p value of 
<0.05 as per chi squared test. Therefore we reject the null hypothesis that there is no 
difference in comparison of fundal height and gestational age vs. type of mole. 
Discussion  
Majority of the patients with complete mole had fundal height measurements 
greater than gestational age (91.67%). Majority of the patients with partial mole had 
fundal height measurements greater than gestational age (50.00%). The occurrence of 
fundal height measurements greater than gestational age status was significantly 
higher in complete mole group compared to partial mole group a percentage 
difference of 41.67% (45% higher). This difference is significant with a p-value of 
0.0491 as per chi squared-test.  
Conclusion  
In this study we can safely conclude that complete mole presents significantly 
higher with fundal height measurements greater than gestational age compared to 
partial mole among patients with molar pregnancy. 
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                                      DISCUSSION 
 ẞ hcg has been an excellent tool for diagnosing and monitoring therapeutic 
response in GTD, the average time around which β-hCG reverts back to normal is 
around 8-9 weeks in the post evacuation period. But routine follow up till this period 
may not be possible due to loss of compliance. In our study, patients with molar 
pregnancy were subjected to uterine artery Doppler study before and after evacuation 
and the efficacy of uterine artery resistance index in predicting resolution or 
persistence of disease earlier than β-hCG was observed. 
1. Maternal Age: 
In our study the age group of patients was between 18 to 42 years, with the 
mean age being 24 yrs.Persistence of molar pregnancy was observed in extremes of 
age group <20 & >40 yrs. 
N.J.sebire et al in 2002 conducted an observational study of maternal age 
distribution from a large scale retrospective obstetric database over a 12 year period 
and he reported that extremes of maternal age had positive relationship for risk of 
molar pregnancy due to defective oocyte. 
2. Educational Status: 
In our study there was no significant difference in the educational status of 
people with either resolution or progression of molar pregnancy. 
 
 89  
 
3. Parity: 
In our study 17 patients were primi para, 10 were G2P1L1, 6 patients had 
history of 1 previous miscarriage and 1 patient had 3 previous miscarriages, there is 
no significant difference in the parity status of both groups. 
 4. Presenting Complaints: 
In our study, 31 patients presented with bleeding per vaginum, one patient with 
hyperemesis, six patients were referred as sonographically detected molar pregnancy 
and one as blighted ovum. Bleeding per vaginum was the most common presenting 
symptom among both the groups. 
5. Gestational Age: 
The mean gestational age of presentation was 11 weeks in our study group, 
since prenatal care is sought much earlier nowadays. 
6. Fundal Height Larger For Gestational Age: 
In our study, the occurrence of fundal height greater than gestational age status 
was significantly higher in complete mole group compared to partial mole group. 
Larger uterine size for dates is seen due to trophoblastic hyperplasia and hemorrhage. 
 
 
 
 90  
 
7. Hemoglobin: 
The mean hemoglobin level in our study group was around 8.3%, vaginal bleeding 
was severe enough to cause symptomatic anemia and most of these patients were 
transfused in the pre evacuation period. 
8. USG Diagnosis: 
In our study sonographically diagnosed complete mole was seen in 36 patients 
and partial mole in 4 patients, which correlated with histopathological examination of 
products of conceptus. 
9. Corpus Luteal Cyst: 
In our study occurrence of corpus luteal cyst was observed in 3 patients due to 
elevated circulating ẞ hcg levels and the cyst resolved in the post evacuation period 
10.ẞhCG Levels: 
In our study, The mean serum  ßhCG levels was significantly lesser in MP 
resolution group compared to MP progression group by a mean difference of 7364.99 
mIU/L (91% more lesser). During the preevacuation period there was a 11 times 
increase in tire of mean serum ßhCG levels in MP progression group compared to MP 
resolution group which came down to 8 times in 48 hrs post evacuation period, 6 
times in 2nd week post evacuation period and started to increase to 33 times more in 
4th week post evacuation period and finally it was 3838 times increased at 8th week 
post evacuation period. 
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11. Uterine Artery Resistance Index: 
In our study, the mean uterine artery resistance index was significantly higher 
in MP resolution group compared to MP progression group during postevcuation 
period by a mean difference of 0.33 (39% higher).  
The mean uterine artery resistance index was significantly higher in MP 
progression group during preevacuation compared to post evacuation period. 
This  fall in UARI in the MP progression group in the post evacuation period is 
due to the inherent character of trophoblast to invade and destroy uterine vasculature, 
forming low resistance lacunas .Similar observation was made by Maymon et al,that 
there was a fall in the UARI in the post evacuation visit of people with persistent 
molar pregnancy 
12. Time When ẞhcg Reaches Normal: 
In our study, Majority of the patients in MP resolution group had time when ẞ 
HCG reaches normal between 4- 8 weeks. Majority of the patients in MP progression 
group had time when ẞ HCG reaches normal only after chemotherapy. 
Cameron et al observed that it would take around 4-12 weeks for ẞhcg to reach 
normal values in the post evacuation period. 
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13. UARI With ẞhCG: 
In our study, the incidence of ↑UARI with ↓ẞHCG was significantly higher in 
MP resolution group compared to MP progression group by a percentage difference of 
80.00% the incidence of ↓UARI with ↑ or plateau ẞHCG was significantly higher in 
MP progression group compared to MP resolution group by a percentage difference of 
80.00%. Thus 1 measurement increase in UARI causes 77.80 mIU/L decreases in 
ẞHCG levels. The increase in levels of UARI correlates negatively and strongly with 
the decrease in ẞHCG. 
Similar observation were made by Kawano et al and Chan et al that ↑UARI 
was associated with ↓ẞHCG in the post molar evacuation. 
14. Associated Features: 
Majority of the patients in MP resolution group had anemia as the main 
associated feature (66.67%). Majority of the patients in MP progression group had 
anemia, hyperemesis and pulmonary nodule as the main associated features (25.00%).  
The occurrence of associated features was significantly lower in MP resolution group 
compared to MP progression group a percentage difference of 83.33%. 
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SUMMARY 
 This study was conducted in Department of obstetrics and gynecology, 
Government Rajaji Hospital, Madurai Medical College, Madurai. The study 
was conducted to observe the role of uterine artery Doppler in earlier prediction 
of resolution or persistence of molar pregnancy 
 40 patients of molar pregnancy were observed, resolution was seen in 36 
patients, persistence of molar pregnancy was seen in 4 patients. 
 There was a significant fall in post evacuation ẞ-hCG values in patients with 
resolution of molar pregnancy and rise in post evacuation ẞ-hCG values in 
patients with progression of molar pregnancy. 
 The average time for the ẞ-hCG values to become normal was around 4-8 
weeks in the molar pregnancy resolution group, while in patients with 
persistence ẞ-hCG values became normal only after chemotherapy. 
 There was a significant fall in post evacuation UARI in patients with 
persistence of molar pregnancy, while there was a significant rise in the post 
evacuation UARI in patients with resolution of molar pregnancy. 
 A strong correlation is observed with the post evacuation rise in UARI with fall 
in ẞ hcg and vice versa. 
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CONCLUSION 
 
In our study we concluded that Uterine Artery Resistance Index (UARI) is a 
non invasive,reproducible and reliable diagnostic approach in earlier prediction of 
resolution or persistence of Gestational Trophoblastic Disease in conjunction with 
βhCG. 
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QUESTIONNAIRE 
 
NAME:                                                                                            UNIT: 
AGE:                                                                                                IP.NO: 
OBSTETRIC CODE: 
H/O PRESENTING ILLNESS: 
ASSO FEATURES OF HYPERTHYROIDISM/GHT: 
PAST HISTORY: H/O DM,HT,HEART DISEASE,HYPOTHYROIDISM 
CHRONIC DRUG INTAKE: 
MENSTRUAL HISTORY: 
DATE OF LMP: 
FAMILY HISTORY: 
H/O CARCINOMA: 
GENERAL EXAMINATION 
HEIGHT:                                                         PEDAL EDEMA: 
WEIGHT:                                                        SPINE: 
ANEMIA:                                                        BREAST: 
THYROID:                                                      GAIT: 
SYSTEMIC EXAMINATION 
PULSE:                                                            CVS: 
BLOOD PRESSURE:                                      RS: 
   
 
PER SPECULAM:                                          CNS: 
PER VAGINUM:                                            PER ABDOMEN: 
INVESTIGATIONS: 
Hb% 
BLOOD GROUPING & TYPING 
RBS 
BLOOD UREA 
SERUM CREATININE 
LFT 
URINE SUGAR 
URINE ALBUMIN 
USG ABDOMEN & PELVIS 
CONSENT PAPERS 
NAME:                                                                                             UNIT: 
AGE:                                                                                                 IP NO: 
PRESENT HISTORY:                                                                     LMP: 
PAST HISTORY: 
OBSTETRIC HISTORY: 
Consent for uterine artery Doppler study in the pre&post evacuation period 
                                                                                     --------------------------------- 
 
   
 
ABBREVIATIONS 
 
β –hCG: - Beta human chorionic gonadotropin 
UARI    : - Uterine Artery Doppler Resistance Index 
USG      : - Ultra sonogram 
HD        : - Hydatidiform mole 
MP        : - Molar pregnancy 
CM        : - Complete mole 
PM        : - Partial mole 
GTN      : - Gestational Trophoblastic Neoplasia 
GTD      : - Gestational Trophoblastic Disease 
PSTT     : - Placental Site Trophoblastic Tumor 
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A B C D E F G H I J K L M N O
                    Post evacuation ẞHCG
S.No Name Age Educational status Parity Presenting c/o Gestational age Fundal height Hb % USG diagnosis Corpus Luteal cyst Preevacuation ẞHCG 48 hrs 2nd wk 4th wk
1 Meena 21 Higher secondary G2P1L1 Bleeding PV 10 weeks 12-14 weeks 7.8 CM 3943 1020 302 15.7
2 Latha 18 10th Primi Bleeding PV 12 weeks 14-16 weeks 8 CM 2150 1016 976 3000
3 Sivaranjani 18 10th Primi Bleeding PV 10 weeks 12-14 weeks 7.6 CM 2612 763 122 22
4 Ambikavathy 27 BA G3P1L1A1 Bleeding PV 11 weeks 12-14 weeks 8 CM 1892 206 145 30
5 Periyatchi 28 Degree holder G2P1L1 Ref as USG shows H.mole 10 weeks 12-14 weeks 8.4 CM 1723 212 98 10
6 Poonkothai 26 B.Tech G5P1L1A3 Ref as USG shows H.mole 10 weeks 12-14 weeks 7.8 CM 2145 324 76 12
7 Seetha 26 Higher secondary G3P1L1A1 Bleeding PV 10 weeks 12-14 weeks 8 CM 976 201 98 16
8 Viayalakshmi 19 Higher secondary Primi Bleeding PV,Hyperemesis 10 weeks 12-14 weeks 10.2 CM 1385 378 76 24
9 Ashmath agina 18 10th G2A1 Bleeding PV 16 weeks 16-18 weeks 7.8 CM 2067 216 119 52
10 Divya 24 Bsc Primi Bleeding PV 12 weeks 14-16 weeks 8 CM 1078 221 96 48
11 Pandiselvi 32 Higher secondary G2P1L1 Bleeding PV 19 weeks 22 weeks 7.6 CM 3167 673 118 29
12 Jothi 22 10th G2P1L1 Bleeding PV 10 weeks 12 weeks 10.6 Partial Mole 1343 503 76 4
13 Annakili 29 Higher secondary G3P1L1A1 Bleeding PV 11 weeks 14-16 weeks 9.8 CM 1876 532 182 36
14 Pavithra 22 10th G3P1L1A1 Bleeding PV 12 weeks 14-16 weeks 7.8 CM 1179 625 134 20
15 Mohanapriya 20 10th Primi Bleeding PV,Hyperemesis 10 weeks 12-14 weeks 10.4 CM 1290 382 1029 1360
16 Malar 26 8th Primi Bleeding PV 10 weeks 10-12 weeks 8.2 CM 986 276 86 18
17 Suganya 20 Higher secondary Primi Bleeding PV 14 weeks 12-14 weeks 10.4 Partial Mole 2006 876 114 68
18 Tamilselvi 22 Polytechnic G3P1L1A1 Ref as USG shows H.mole 10 weeks 12-14 weeks 8.4 CM 1891 439 153 92
19 Nambuselvi 42 2nd Primi Bleeding PV 12 weeks 14 weeks 7.6 Partial Mole 114560 12768 830 17.8
20 Vijaya 35 Nil G2P1L1 Bleeding PV 12 weeks 12-14 weeks 10 CM 1298 312 101 43
21 Muthupandi 29 Higher secondary G2P1L1 Bleeding PV 12 weeks 14-16 weeks 8.2 CM 1786 301 165 89
22 Maharani 28 10th G3P2L2 Bleeding PV 10 weeks 12-14 weeks 9.2 CM 2651 512 134 98
23 Mareeshwari 26 Higher secondary G2P1L1 Bleeding PV 10 weeks 12 weeks 10.6 CM 889 219 97 29
24 Sundaravalli 33 Higher secondary Primi ?Blighted ovum 10 weeks 12 weeks 10.2 CM Yes 3012 1521 131 65
25 Suganya 22 Higher secondary Primi Ref as USG shows H.mole 10 weeks 16 weeks 7.6 CM 3298 1213 482 101
26 Panjavarnam 35 Higher secondary G2P1L1 Bleeding PV 12 weeks 14-16 weeks 7.4 CM 2550 621 231 82
27 Nandhini 19 Polytechnic G2A1 Bleeding PV 10 weeks 12-14 weeks 8.4 CM Yes 14892 1869 1071 1122
28 Manonmani 19 10th Primi Bleeding PV 10 weeks 12-14 weeks 7.6 CM 912 201 82 21
29 Kaleeswari 22 10th G2P1L1 Ref as USG shows H.mole 10 weeks 12-14 weeks 8 CM Yes 12420 1275 610 60
30 Sundarammal 25 Nil G3P2L1 Bleeding PV 12 weeks 14-16 weeks 7.6 CM 35980 1600 712 53
31 Selvi 27 10th G3P2L1 Ref as USG shows H.mole 12 weeks 14-16 weeks 7.2 CM 1287 331 102 76
32 Bhavani 24 Higher secondary Primi Bleeding PV 10 weeks 12-14 weeks 8 CM 912 112 76 21
33 Bhagavathi 18 8th Primi Bleeding PV 12 weeks 14-16 weeks 8.2 CM 865 124 85 15
34 Meena 22 Higher secondary G2P1L1 Bleeding PV 10 weeks 12-14 weeks 7.8 CM 1943 389 120 56
35 Malliga 21 Nil G3P1L0A1 Bleeding PV 12 weeks 12 weeks 7.2 Partial Mole 954 110 43 2
36 Sudha 25 Nil Primi Bleeding PV 10 weeks 12-14 weeks 8.2 CM 1814 412 92 21
37 Eshwari 25 Higher secondary Primi Bleeding PV 12 weeks 14-16 weeks 7.8 CM 1487 412 121 76
38 Kavitha 28 Nil G3P2L2 Bleeding PV 10 weeks 12-14 weeks 8 CM 1272 159 91 28
39 Priya 24 3rd Primi Bleeding PV 12 weeks 14-16 weeks 8.2 CM 1934 316 104 63
40 Sivarani 21 Nil Primi Bleeding PV 10 weeks 12-14 weeks 8.4 CM 962 154 84 18
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            Uterine artery RI
8th wk Preevacuation Postevacuation ẞ HCG reaches normal at MP Resolution (↑UARI with ↓ẞHCG) MP progression(↓UARI with ↑ or plateau ẞHCG Asso features
0.1 0.6 0.9 8 Weeks Yes No Anemia
2921 0.6 0.4 after chemotherapy NO YES Anemia
0.1 0.6 0.9 8 Weeks Yes No Anemia
<0.5 0.7 1 8 Weeks Yes No Anemia
<0.2 0.6 0.92 8 Weeks Yes No Anemia
<0.2 0.6 0.8 8 Weeks Yes No Anemia
<0.1 0.58 0.9 8 Weeks Yes No Anemia
<0.4 0.6 0.9 8 Weeks Yes No Hyperemesis
<0.2 0.5 0.9 8 Weeks Yes No Anemia
<0.5 0.6 1 8 Weeks Yes No Anemia
0.4 0.5 0.8 12 Weeks Yes No Anemia
<0.1 0.6 0.9 4 weeks Yes No Nil
<0.4 0.5 0.9 8 Weeks Yes No Nil
<0.1 0.7 0.9 8 Weeks Yes No Anemia
58 0.7 0.56 after chemotherapy NO YES Hyperemesis
<0.1 0.57 0.7 8 Weeks Yes No Anemia
2 0.5 0.8 8 weeks Yes No Nil
<0.1 0.7 1  10 Weeks Yes No Anemia
2.2 0.6 0.5 after chemotherapy NO YES pulmonary nodule
<0.4 0.6 0.8 8 Weeks Yes No Nil
<0.1 0.5 0.8 8 weeks Yes No Anemia
<0.4 0.6 0.8 8 Weeks Yes No Nil
<0.4 0.5 0.8 8 Weeks Yes No Nil
<0.1 0.6 0.8 8 Weeks Yes No Hyperemesis
<0.4 0.5 0.8 8 weeks Yes No Hyperemesis
<0.4 0.6 0.8 8 Weeks Yes No Anemia
812 0.7 0.6 after chemotherapy NO YES Anemia,hyperemesis
<0.1 0.6 0.8 8 Weeks Yes No Anemia
0.2 0.6 0.8 8 Weeks Yes No Anemia,Hyperemesis
0.4 0.5 0.8 8 Weeks Yes No Hyperemesis
0.1 0.6 0.9 8 Weeks Yes no Anemia
<0.2 0.6 0.9 8 Weeks Yes No Anemia
<0.4 0.5 0.8 8 Weeks Yes No Hyperemesis
0.1 0.5 0.8 8 Weeks Yes No Anemia
<0.1 0.5 0.7 4 weeks Yes No Anemia
<0.1 0.5 0.8 8 Weeks Yes No Anemia
<0.1 0.6 0.9 8 Weeks Yes No Anemia
<0.1 0.5 0.8 8 Weeks Yes no Anemia
<0.1 0.6 0.9 8 Weeks Yes No Anemia
<0.1 0.6 0.8 8 Weeks Yes No Anemia
